Plus Therapeutics, SpectronRx Collaborate to Manufacture Rhenium Obisbemeda Radiotherapy

MT Newswires Live11-06

Plus Therapeutics (PSTV) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.

Financial details weren't disclosed.

Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.

The partnership aims to strengthen supply chain redundancy for Plus Therapeutics, ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.

Shares of Plus Therapeutics were down 6.6% in recent Wednesday trading.

Price: 1.27, Change: -0.09, Percent Change: -6.62

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481347369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481347369","market":"sg","top_or_hot":-1,"title":"Plus Therapeutics, SpectronRx Collaborate to Manufacture Rhenium Obisbemeda Radiotherapy","media":"MT Newswires Live","content":"<html><body><p> Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PSTV) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.</p><p>Financial details weren't disclosed.</p><p>Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.</p><p>The partnership aims to strengthen supply chain redundancy for Plus Therapeutics, ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.</p><p>Shares of Plus Therapeutics were down 6.6% in recent Wednesday trading.</p><p>Price: 1.27, Change: -0.09, Percent Change: -6.62</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics, SpectronRx Collaborate to Manufacture Rhenium Obisbemeda Radiotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics, SpectronRx Collaborate to Manufacture Rhenium Obisbemeda Radiotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 23:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Plus Therapeutics (PSTV) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.Financial ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTV","symbol_name":"Plus Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481347369","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481347369","pubTimestamp":1730908012,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Plus Therapeutics  said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.Financial details weren't disclosed.Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.The partnership aims to strengthen supply chain redundancy for Plus Therapeutics, ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.Shares of Plus Therapeutics were down 6.6% in recent Wednesday trading.Price: 1.27, Change: -0.09, Percent Change: -6.62","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSTV":"Plus Therapeutics, Inc.","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Plus Therapeutics与SpectronRx合作生产铼Obisbemeda放射疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":0.6,"PSTV":0.6},"content_text":"Plus Therapeutics (PSTV) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.Financial details weren't disclosed.Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.The partnership aims to strengthen supply chain redundancy for Plus Therapeutics, ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.Shares of Plus Therapeutics were down 6.6% in recent Wednesday trading.Price: 1.27, Change: -0.09, Percent Change: -6.62","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481347369"}